Moderna CEO Stéphane Bancel said he worries deeply about bioterrorism and questioned if Europe is sufficiently prepared for another pandemic [1].
These warnings highlight a critical gap in global health security as nations move further away from the immediate crisis of the COVID-19 era. If Europe lacks the infrastructure to respond to a biological attack or a natural outbreak, the economic and human costs could mirror or exceed previous global emergencies.
During an interview on Monday, Bancel said the risk of biological threats is persistent [1]. He said the current state of readiness in Europe may be inadequate to handle a large-scale health crisis [1]. This concern aligns with broader expert perspectives on the fragility of international health systems.
Dr. Francis Collins said the world is unprepared for another pandemic like COVID-19 in the next decade [2]. The convergence of these warnings suggests that the lessons learned from 2020 have not yet been fully institutionalized into permanent defense strategies.
Beyond pandemic preparedness, Bancel discussed the ongoing work at Moderna regarding cancer treatments [1]. The company continues to leverage mRNA technology to develop therapies that target malignancies, expanding the utility of the platform beyond infectious diseases [1].
Bancel's comments come as a call for increased vigilance and investment in rapid-response capabilities. He said the threat of bioterrorism remains a significant concern for global stability [1].
“"I worry deeply about bioterrorism."”
The warnings from Bancel and Collins indicate a perceived decline in pandemic vigilance. By linking bioterrorism to general pandemic preparedness, Bancel is framing biological security not just as a medical issue, but as a national security priority for European governments.
